Incidence and Predictors of an Abnormal Liver Function Test Among 674 Systemic Sclerosis Patients: A Cohort Study

References

• De Santis M, Crotti C, Selmi C. Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol. 2013;27(4):543–551. doi:10.1016/j.bpg.2013.06.016
   PubMed Web of Science ®Google Scholar
• Kojima H, Uemura M, Sakurai S, et al. Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol. 2002;37:617–625.
   PubMed Web of Science ®Google Scholar
• Salem GIA, Abdulrahman AA. Evaluation of liver function tests in scleroderma patients. Rheumatol Int. 2012;32:2371–2375.
   PubMed Web of Science ®Google Scholar
• Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol. 2011;2011:976427.
   PubMedGoogle Scholar
• Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum. 2005;52:2415–2424.
   PubMed Web of Science ®Google Scholar
• Assassi S, Fritzler MJ, Arnett FC, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009;36:2250–2256.
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T. Clinical, Serological and Genetic Study in Patients with CREST Syndrome. Intern Med. 2000;39:451–456.
   PubMed Web of Science ®Google Scholar
• Rodrigues CEM, Borges CL, de Carvalho JF. Diffuse systemic sclerosis and autoimmune hepatitis: a unique association. Clin Rheumatol. 2010;29:799–801.
   PubMed Web of Science ®Google Scholar
• Fraile G, Rodríguez-García JL, Moreno A. Primary sclerosing cholangitis associated with systemic sclerosis. Postgrad Med J. 1991;67:189–192.
   PubMed Web of Science ®Google Scholar
• Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun. 2013;41:1–5. doi:10.1016/j.jaut.2013.01.010
   PubMed Web of Science ®Google Scholar
• Marie I, Levesque H, Tranvouez J, et al. Autoimmune hepatitis and systemic sclerosis: a new overlap syndrome? Rheumatology. 2001;40(1):102–106. doi:10.1093/rheumatology/40.1.102
   PubMed Web of Science ®Google Scholar
• Yabe H, Noma K, Tada N, Mochizuki S, Nagano M. A Case of CREST Syndrome with Rapidly Progressive Liver Damage. Intern Med. 1992;31(1):69–73. doi:10.2169/internalmedicine.31.69
   PubMed Web of Science ®Google Scholar
• Toyoda M, Yokomori H, Kaneko F, et al. Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap Syndrome Concomitant with Systemic Sclerosis, Immune Thrombocytopenic Purpura. Internal Med. 2009;48(23):2019–2023. doi:10.2169/internalmedicine.48.2687
   PubMed Web of Science ®Google Scholar
• Ngo Mandag N, Van Gossum M, Rickaert F, Golstein M. [Autoimmune hepatitis and CREST syndrome]. Rev Med Brux. 2007;28:528–531.
   PubMedGoogle Scholar
• Assandri R, Monari M, Montanelli A. Development of systemic sclerosis in patients with autoimmune hepatitis: an emerging overlap syndrome. Gastroenterol Hepatol Bed Bench. 2016;9:211–219.
   PubMedGoogle Scholar
• Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut. 2001;49:589–594.
   PubMed Web of Science ®Google Scholar
• Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722.
   PubMed Web of Science ®Google Scholar
• Washington MK. Autoimmune liver disease: overlap and outliers. Modern Pathology. 2007;20:S15–30.
   PubMed Web of Science ®Google Scholar
• You BC, Jeong SW, Jang JY, et al. Liver cirrhosis due to autoimmune hepatitis combined with systemic sclerosis. Korean J Gastroenterol. 2012;59:48–52.
   PubMedGoogle Scholar
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–590.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–1755.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Cohen SM, Lim JK, Clinical Guideline ACG. Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112:18–35.
   PubMed Web of Science ®Google Scholar
• Brennan P, Silman A, Black C, et al. Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol. 1992;31:457–460.
   PubMedGoogle Scholar
• Black CM. Measurement of skin involvement in scleroderma. J Rheumatol. 1995;22:1217–1219.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.
   PubMed Web of Science ®Google Scholar
• Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21:S29–31.
   PubMed Web of Science ®Google Scholar
• Savarino E, Furnari M, de Bortoli N, et al. Gastrointestinal involvement in systemic sclerosis. Presse Med. 2014;43:e279–291.
   PubMed Web of Science ®Google Scholar
• Foocharoen C, Peansukwech U, Mahakkanukrauh A, et al. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: a cohort study. Int J Rheum Dis. 2020;23:945–957.
   PubMed Web of Science ®Google Scholar
• Manco M, Alisi A, Real JMF, et al. Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. J Hepatol. 2011;55:647–653.
   PubMed Web of Science ®Google Scholar
• Vos B, Moreno C, Nagy N, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg. 2011;74:389–394.
   PubMed Web of Science ®Google Scholar
• Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2013;47:280–286.
   PubMed Web of Science ®Google Scholar
• Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AKMK. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J Gastroenterol. 2014;33:452–457.
   PubMedGoogle Scholar
• Leung JCF, Loong TCW, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65:54–64.
   PubMed Web of Science ®Google Scholar
• Cruz A, Bugianesi E, George J, et al. 379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2014;146:S–909.
   Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.
   PubMed Web of Science ®Google Scholar
• Cruz ACD, Bugianesi E, George J, et al. 379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2014;5(146):S909.
   Google Scholar
• Roongrawee T, Thanapirom K, Chaiteerakij R, Komolmit P, Phathong C, Treeprasertsuk S. Drugs-Herbs-Dietary Supplements-induced Liver Injury: a Hidden but Emerging Clinical Problem. J Med Assoc Thai. 2020;103:92–98.
   Google Scholar
• Leroi C, Adam P, Khamduang W, et al. Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis. Int J Infect Dis. 2016;51:36–43.
   PubMed Web of Science ®Google Scholar
• Wasitthankasem R, Pimsingh N, Treesun K, et al. Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: burden Assessment toward HCV Elimination. Am J Trop Med Hyg. 2020;103:175–182.
   PubMed Web of Science ®Google Scholar
• Jacobsen S, Halberg P, Ullman S, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol. 1998;37:39–45.
   PubMedGoogle Scholar
• Posthuma WF, Ledeboer M, Masclee AA, et al. Do patients with systemic sclerosis have abnormal gallbladder function? Eur J Gastroenterol Hepatol. 1997;9:675–677.
   PubMed Web of Science ®Google Scholar
• Stern EP, Denton CP. The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am. 2015;41:367–382.
   PubMed Web of Science ®Google Scholar
• Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69:1127–1138.
   PubMed Web of Science ®Google Scholar
• Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17:432–437.
   PubMed Web of Science ®Google Scholar
• Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest. 2013;144:1346–1356.
   PubMed Web of Science ®Google Scholar
• Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155:565–586.
   PubMed Web of Science ®Google Scholar
• Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: evidence-based review. Curr Opin Rheumatol. 2007;19:611–618.
   PubMed Web of Science ®Google Scholar
• Lee SW, Kim BK, Park JY, et al. Disease duration and Medsger’s severity score are associated with significant liver fibrosis in patients with systemic sclerosis. Clin Exp Rheumatol. 2015;33:S68–74.
   PubMed Web of Science ®Google Scholar
• Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003;21:S42–46.
   PubMed Web of Science ®Google Scholar
• Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig. 2006;26:55–62.
   PubMed Web of Science ®Google Scholar
• Almaabdi K, Ahmad Z, Johnson SR. Advanced Autoantibody Testing in Systemic Sclerosis. Diagnostics. 2023;13:851.
   Web of Science ®Google Scholar
• Powell A, McNeil J. Primary sclerosing cholangitis associated with CREST (calcinosis, Raynaud phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia) in an elderly woman: a case report. J Med Case Rep. 2015;9:272.
   PubMedGoogle Scholar
• Mathur T, Manadan AM, Thiagarajan S, Hota B, Block JA. Serum transaminases are frequently elevated at time of diagnosis of idiopathic inflammatory myopathy and normalize with creatine kinase. J Clin Rheumatol. 2014;20:130–132.
   PubMed Web of Science ®Google Scholar
• Volochayev R, Csako G, Wesley R, Rider LG, Miller FW. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatol J. 2012;6:54–63.
   PubMedGoogle Scholar